Guy Georges

This inventor holds 74 USPTO granted patents and 62 published patent applications, plus 9 CIPO patents and 40 EPO patents, primarily in Bispecific Antibodies (CPC class C07K). Top assignees: Hoffmann-La Roche Inc., Roche Glycart Ag, Roche Palo Alto LLC. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guy Georges. Retrieved from https://idiyas.com/inventor/guy-georges

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 74 (Patent Applications = 62)

% Patents Active = 64.9

CIPO Patents = 9 (Patent Applications = 32)

EPO Patents = 40 (Patent Applications = 78)

Average Co-Inventor Count = 6.9

ph-index = 9

Forward Citations = 373(Granted Patents)

Forward Citations (Not Self Cited) = 328(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Habach, DE (2003 - 2024)
Penzberg, DE (2023 - 2024)

Company Filing History:

65 out of 5,026

Hoffmann-La Roche Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

Tumor-Targeted Molecules

Multispecific Antibodies

Avid-Binding Antibodies

Humanized Antibodies

Covalently Linked Conjugates

Anti-VEGF Antibodies

Anti-HER3 Antibodies

Affinity Tailoring

NKG2D Binding

Blood Brain Barrier Shuttles

DR5 Specific Antibodies

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630622 - BISPECIFIC ANTI-CCL2 ANTIBODIES (2026-05-19),

2. 12600781 - TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES (2026-04-14),

3. 12565536 - Method for generating avid-binding multispecific antibodies (2026-03-03),

4. 12297290 - Method for generating multispecific antibodies from monospecific antibodies (2025-05-13),

5. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

6. 12252533 - Anti-transferrin receptor antibodies with tailored affinity (2025-03-18),

7. 12227594 - Bispecific 2+1 contorsbodies (2025-02-18),

8. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

9. 12145994 - Bispecific antigen binding molecules capable of specific binding to CD40 and to fap (2024-11-19),

10. 12103967 - Bispecific anti-CCL2 antibodies (2024-10-01),

11. 12043651 - Compbody—a multivalent target binder (2024-07-23),

12. 12023378 - Covalently linked antigen-antibody conjugates (2024-07-02),

13. 11827711 - Antibodies binding to NKG2D (2023-11-28),

14. 11820816 - Anti-VEGF antibodies and methods of use (2023-11-21),

15. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),

Title: Guy Georges: A Visionary Innovator Shaping the Future

Introduction: Guy Georges, a brilliant inventor hailing from Habach, Germany, has left an indelible mark on the world of innovation with his exceptional work.

Latest Patents: Among his impressive portfolio of 62 patents, Guy Georges' latest inventions include groundbreaking developments such as antibodies binding to NKG2D and Anti-VEGF antibodies, revolutionizing the fields of immunotherapy and disease treatment.

Career Highlights: Having worked at prestigious companies like Hoffmann-La Roche Inc., Guy Georges has consistently demonstrated his prowess in translating cutting-edge ideas into impactful solutions.

Collaborations: Throughout his career, Guy Georges has collaborated closely with esteemed professionals like Ekkehard Moessner and Olaf Mundigl, fostering a culture of innovation and excellence in his projects.

Conclusion: Guy Georges stands as a true pioneer in the realm of innovation, with a remarkable ability to bring visionary concepts to life, thereby positively influencing society and advancing the frontiers of scientific discovery.

Profile summary based on public USPTO records.